Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引：0
|
作者：
Mats Någård
Mei-Lin Ah-See
Karen So
Marit Vermunt
Fiona Thistlethwaite
Mariette Labots
Patricia Roxburgh
Alain Ravaud
Mario Campone
Liselot Valkenburg-van Iersel
Lone Ottesen
Yan Li
Ganesh Mugundu
机构：
[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology
[2] AstraZeneca,Late Stage Development, Oncology R&D
[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D
[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences
[5] The Christie NHS Foundation Trust and University of Manchester,undefined
[6] Cancer Center Amsterdam,undefined
[7] Amsterdam UMC,undefined
[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined
[9] Bordeaux University Hospital,undefined
[10] ICO – Site René,undefined
[11] Maastricht University Medical Centre,undefined
[12] AstraZeneca,undefined
[13] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 108
页数：11
相关论文
共 50 条
  • [21] The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
    Gupta, Neeraj
    Hanley, Michael J.
    Venkatakrishnan, Karthik
    Wang, Bingxia
    Sharma, Sunil
    Bessudo, Alberto
    Hui, Ai-Min
    Nemunaitis, John
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (10): : 1288 - 1295
  • [22] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Lowery, Maeve A.
    Goyal, Lipika
    Tap, William D.
    Pandya, Shuchi S.
    Manyak, Erika
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Gliser, Camelia
    Judge, Molly Prahl
    Agresta, Sam
    Yang, Hua
    Dai, David
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 433 - 444
  • [23] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Mori, Yuko
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
  • [24] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Bin Fan
    Ingo K. Mellinghoff
    Patrick Y. Wen
    Maeve A. Lowery
    Lipika Goyal
    William D. Tap
    Shuchi S. Pandya
    Erika Manyak
    Liewen Jiang
    Guowen Liu
    Tara Nimkar
    Camelia Gliser
    Molly Prahl Judge
    Sam Agresta
    Hua Yang
    David Dai
    Investigational New Drugs, 2020, 38 : 433 - 444
  • [25] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Yoichi Naito
    Yasutoshi Kuboki
    Masafumi Ikeda
    Kenichi Harano
    Nobuaki Matsubara
    Shigeyuki Toyoizumi
    Yuko Mori
    Natsuki Hori
    Takashi Nagasawa
    Takahiro Kogawa
    Investigational New Drugs, 2021, 39 : 1568 - 1576
  • [26] A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
    Leijen, Suzanne
    Soetekouw, Patricia M. M. B.
    Evans, T. R. Jeffry
    Nicolson, Marianne
    Schellens, Jan H. M.
    Learoyd, Maria
    Grinsted, Lynda
    Zazulina, Victoria
    Pwint, Thinn
    Middleton, Mark
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1619 - 1628
  • [27] A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors
    Falchook, Gerald
    Patnaik, Amita
    Richardson, Debra L.
    Harvey, R. Donald
    Sharma, Manish R.
    Hafez, Navid
    Hamilton, Erika
    Piha-Paul, Sarina A.
    Barve, Minal
    Wise-Draper, Trisha
    Patel, Manish R.
    Dowlati, Afshin
    Pascuzzo, Joseph
    Tang, Shou-Ching
    Faltermeier, Christina
    Malinowska, Izabela A.
    Shtessel, Luda
    Striha, Alina
    Potocka, Elizabeth
    CLINICAL THERAPEUTICS, 2024, 46 (03) : 228 - 238
  • [28] A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors
    Mostafa, Nael M.
    Chiu, Yi-Lin
    Rosen, Lee S.
    Bessudo, Alberto
    Kovacs, Xenia
    Giranda, Vincent L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 583 - 591
  • [29] A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors
    Nael M. Mostafa
    Yi-Lin Chiu
    Lee S. Rosen
    Alberto Bessudo
    Xenia Kovacs
    Vincent L. Giranda
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 583 - 591
  • [30] The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
    Sharma, Sunil
    Britten, Carolyn D.
    Mortimer, Joanne
    Kulkarni, Swarupa
    Quinlan, Michelle
    Liu, Angela
    Scott, Jeffrey W.
    George, Daniel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 867 - 874
12345